Switch theme
Sign up to access all valuation multiples
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.
2012
391
LTM Revenue n/a
LTM EBITDA n/a
$454M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EirGenix has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, EirGenix achieved revenue of $30.5M and an EBITDA of -$11.7M.
EirGenix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EirGenix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $30.9M | $30.5M | XXX | XXX | XXX |
| Gross Profit | $22.8M | $7.1M | XXX | XXX | XXX |
| Gross Margin | 74% | 23% | XXX | XXX | XXX |
| EBITDA | -$20.1M | -$11.7M | XXX | XXX | XXX |
| EBITDA Margin | -65% | -39% | XXX | XXX | XXX |
| Net Profit | -$3.5M | -$27.6M | XXX | XXX | XXX |
| Net Margin | -11% | -91% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, EirGenix's stock price is TWD 62 (or $2).
EirGenix has current market cap of TWD 18.7B (or $566M), and EV of TWD 15.0B (or $454M).
See EirGenix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $454M | $566M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, EirGenix has market cap of $566M and EV of $454M.
EirGenix's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate EirGenix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for EirGenix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $454M | XXX | XXX | XXX |
| EV/Revenue | 14.9x | XXX | XXX | XXX |
| EV/EBITDA | -38.7x | XXX | XXX | XXX |
| P/E | -26.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEirGenix's NTM/LTM revenue growth is n/a
EirGenix's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, EirGenix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate EirGenix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for EirGenix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 78% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 108% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EirGenix acquired XXX companies to date.
Last acquisition by EirGenix was XXXXXXXX, XXXXX XXXXX XXXXXX . EirGenix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was EirGenix founded? | EirGenix was founded in 2012. |
| Where is EirGenix headquartered? | EirGenix is headquartered in Taiwan. |
| How many employees does EirGenix have? | As of today, EirGenix has 391 employees. |
| Is EirGenix publicy listed? | Yes, EirGenix is a public company listed on ROCO. |
| What is the stock symbol of EirGenix? | EirGenix trades under 6589 ticker. |
| When did EirGenix go public? | EirGenix went public in 2016. |
| Who are competitors of EirGenix? | Similar companies to EirGenix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of EirGenix? | EirGenix's current market cap is $566M |
| What is the current revenue growth of EirGenix? | EirGenix revenue growth between 2023 and 2024 was -1%. |
| Is EirGenix profitable? | Yes, EirGenix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
